Perspective Therapeutics (CATX) Interest Coverage Ratio Growth (1y) (2011 - 2026)
Perspective Therapeutics (CATX) Interest Coverage Ratio Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -45.18% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 3.52% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 59.82% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -80.85% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.06% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 189.50% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -54.61% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -6.18% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 79.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.80% |
| Dec 31, 2025 | -3,559,690.28% |
| Sep 30, 2025 | 74.93% |
| Jun 30, 2025 | 82.32% |
| Mar 31, 2025 | -431.66% |
| Dec 31, 2024 | 99.80% |
| Sep 30, 2024 | -1,104.41% |
| Jun 30, 2024 | -7,268.35% |
| Mar 31, 2024 | -1,133.49% |
| Mar 31, 2023 | 97.76% |
| Mar 31, 2022 | -10,349.47% |
| Sep 30, 2021 | -154.42% |
| Jun 30, 2021 | 126.81% |
| Mar 31, 2021 | 89.92% |
| Dec 31, 2020 | -53.07% |
| Sep 30, 2020 | 26.13% |
| Jun 30, 2020 | 99.55% |
| Mar 31, 2020 | 97.26% |
| Dec 31, 2019 | 98.49% |
| Sep 30, 2019 | 70.26% |